

Calvin Yu-Chian Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8763413/publications.pdf>

Version: 2024-02-01

129
papers

3,832
citations

156536

32
h-index

156644

58
g-index

131
all docs

131
docs citations

131
times ranked

4088
citing authors

#	ARTICLE	IF	CITATIONS
1	Network pharmacology-based approach of novel traditional Chinese medicine formula for treatment of acute skin inflammation in silico. <i>Computational Biology and Chemistry</i> , 2017, 71, 70-81.	1.1	23
2	Residue-based design of small molecule inhibitor for H1N1, H5N1 and H7N1 mutants. <i>Journal of Molecular Modeling</i> , 2016, 22, 4.	0.8	1
3	Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanoma. <i>International Journal of Nanomedicine</i> , 2015, 10, 3131.	3.3	14
4	When Modern Technology Meets Ancient Traditional Chinese Medicine. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-2.	0.5	4
5	Recent Novel High-Tech Researches in Molecular Biology. <i>BioMed Research International</i> , 2015, 2015, 1-3.	0.9	2
6	Identification of tyrosinase inhibitors from traditional Chinese medicines for the management of hyperpigmentation. <i>SpringerPlus</i> , 2015, 4, 184.	1.2	17
7	Insight into two antioxidants binding to the catalase NADPH binding site from traditional Chinese medicines. <i>RSC Advances</i> , 2015, 5, 6625-6635.	1.7	5
8	Molecular insight and resolution for tumors harboring the H-ras(G12V) mutation. <i>RSC Advances</i> , 2015, 5, 20623-20633.	1.7	4
9	Susceptible gene of stasis-stagnation constitution from genome-wide association study related to cardiovascular disturbance and possible regulated traditional Chinese medicine. <i>BMC Complementary and Alternative Medicine</i> , 2015, 15, 229.	3.7	5
10	Beware of docking!. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 78-95.	4.0	460
11	<i>In Silico</i> Design for Adenosine Monophosphate-Activated Protein Kinase Agonist from Traditional Chinese Medicine for Treatment of Metabolic Syndromes. <i>Evidence-based Complementary and Alternative Medicine</i> , 2014, 2014, 1-16.	0.5	6
12	<i>In Silico</i> Insight into Potent of Anthocyanin Regulation of FKBP52 to Prevent Alzheimer's Disease. <i>Evidence-based Complementary and Alternative Medicine</i> , 2014, 2014, 1-20.	0.5	8
13	Finding Inhibitors of Mutant Superoxide Dismutase-1 for Amyotrophic Lateral Sclerosis Therapy from Traditional Chinese Medicine. <i>Evidence-based Complementary and Alternative Medicine</i> , 2014, 2014, 1-12.	0.5	14
14	Computational Design of Apolipoprotein E4 Inhibitors for Alzheimer's Disease Therapy from Traditional Chinese Medicine. <i>BioMed Research International</i> , 2014, 2014, 1-13.	0.9	11
15	Treatment of Acute Lymphoblastic Leukemia from Traditional Chinese Medicine. <i>Evidence-based Complementary and Alternative Medicine</i> , 2014, 2014, 1-21.	0.5	5
16	Potential Smoothed Inhibitor from Traditional Chinese Medicine against the Disease of Diabetes, Obesity, and Cancer. <i>BioMed Research International</i> , 2014, 2014, 1-12.	0.9	5
17	A possible solution for hair loss by inhibiting corticotropin-releasing factor (CRF) receptor from traditional Chinese medicine. <i>Journal of Biomolecular Structure and Dynamics</i> , 2014, 32, 1613-1623.	2.0	4
18	<i>In Silico</i> Identification of Potent PPAR Agonists from Traditional Chinese Medicine: A Bioactivity Prediction, Virtual Screening, and Molecular Dynamics Study. <i>Evidence-based Complementary and Alternative Medicine</i> , 2014, 2014, 1-19.	0.5	16

#	ARTICLE	IF	CITATIONS
19	Design of Glucagon-Like Peptide-1 Receptor Agonist for Diabetes Mellitus from Traditional Chinese Medicine. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-17.	0.5	1
20	In Silico Design of BACE1 Inhibitor for Alzheimer's Disease by Traditional Chinese Medicine. BioMed Research International, 2014, 2014, 1-14.	0.9	9
21	Investigation of Anti-Infection Mechanism of Lactoferricin and Splunc-1. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-10.	0.5	4
22	In Silico Investigation of Potential Pyruvate Kinase M2 Regulators from Traditional Chinese Medicine against Cancers. BioMed Research International, 2014, 2014, 1-14.	0.9	1
23	Investigation of the Novel Lead of Melanocortin 1 Receptor for Pigmentary Disorders. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-13.	0.5	11
24	Potential Retinoid X Receptor Agonists for Treating Alzheimer's Disease from Traditional Chinese Medicine. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-13.	0.5	6
25	Ligand-Based and Structure-Based Investigation for Alzheimer's Disease from Traditional Chinese Medicine. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-16.	0.5	34
26	Lead Screening for CXCR4 of the Human HIV Infection Receptor Inhibited by Traditional Chinese Medicine. BioMed Research International, 2014, 2014, 1-13.	0.9	2
27	Lead Screening for HIV of C-C Chemokine Receptor Type 5 Receptor Inhibited by Traditional Chinese Medicine. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-10.	0.5	2
28	Lead Screening for HIV-1 Integrase (IN) Inhibited by Traditional Chinese Medicine. BioMed Research International, 2014, 2014, 1-12.	0.9	5
29	Treatment of Rheumatoid Arthritis with Traditional Chinese Medicine. BioMed Research International, 2014, 2014, 1-11.	0.9	27
30	The Inhibition of Folylpolylglutamate Synthetase (folC) in the Prevention of Drug Resistance in <i>Mycobacterium tuberculosis</i> by Traditional Chinese Medicine. BioMed Research International, 2014, 2014, 1-14.	0.9	5
31	Lead Discovery for Alzheimer's Disease Related Target Protein RbAp48 from Traditional Chinese Medicine. BioMed Research International, 2014, 2014, 1-14.	0.9	9
32	In Silico Investigation of Traditional Chinese Medicine Compounds to Inhibit Human Histone Deacetylase 2 for Patients with Alzheimer's Disease. BioMed Research International, 2014, 2014, 1-15.	0.9	12
33	Drug Design of Cyclin-Dependent Kinase 2 Inhibitor for Melanoma from Traditional Chinese Medicine. BioMed Research International, 2014, 2014, 1-17.	0.9	11
34	Pharmacological Chaperone Design for Reducing Risk Factor of Parkinson's Disease from Traditional Chinese Medicine. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-12.	0.5	21
35	Investigation of Estrogen Receptor (ESR1) for Breast Cancer from Traditional Chinese Medicine. BioMed Research International, 2014, 2014, 1-12.	0.9	5
36	Lead Screening for Chronic Obstructive Pulmonary Disease of IKK2 Inhibited by Traditional Chinese Medicine. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-16.	0.5	5

#	ARTICLE	IF	CITATIONS
37	In Silico Investigation of Potential mTOR Inhibitors from Traditional Chinese Medicine for Treatment of Leigh Syndrome. <i>BioMed Research International</i> , 2014, 2014, 1-9.	0.9	6
38	In Silico Investigation of Cytochrome P450 2C9 in relation to Aging Using Traditional Chinese Medicine. <i>Evidence-based Complementary and Alternative Medicine</i> , 2014, 2014, 1-14.	0.5	2
39	In Silico Investigation of Potential PARP-1 Inhibitors from Traditional Chinese Medicine. <i>Evidence-based Complementary and Alternative Medicine</i> , 2014, 2014, 1-13.	0.5	6
40	Potential Protein Phosphatase 2A Agents from Traditional Chinese Medicine against Cancer. <i>Evidence-based Complementary and Alternative Medicine</i> , 2014, 2014, 1-10.	0.5	6
41	An Investigation of Small GTPases in relation to Liver Tumorigenesis Using Traditional Chinese Medicine. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	1
42	Evaluation of Correlation of Cell Cycle Proteins and Ki-67 Interaction in Paranasal Sinus Inverted Papilloma Prognosis and Squamous Cell Carcinoma Transformation. <i>BioMed Research International</i> , 2014, 2014, 1-16.	0.9	14
43	Investigation of Potent Lead for Acquired Immunodeficiency Syndrome from Traditional Chinese Medicine. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	3
44	Insight into HIV of IFN-Induced Myxovirus Resistance 2 (MX2) Expressed by Traditional Chinese Medicine. <i>BioMed Research International</i> , 2014, 2014, 1-14.	0.9	0
45	Potential Mitochondrial Isocitrate Dehydrogenase R140Q Mutant Inhibitor from Traditional Chinese Medicine against Cancers. <i>BioMed Research International</i> , 2014, 2014, 1-10.	0.9	7
46	In Silico Investigation of Potential TRAF6 Inhibitor from Traditional Chinese Medicine against Cancers. <i>BioMed Research International</i> , 2014, 2014, 1-14.	0.9	4
47	Possible Inhibitor from Traditional Chinese Medicine for the β -Form of Calcium-Dependent Protein Kinase Type II in the Treatment of Major Depressive Disorder. <i>BioMed Research International</i> , 2014, 2014, 1-14.	0.9	1
48	Treatment of Cardiovascular Disease by Traditional Chinese Medicine against Pregnane X Receptor. <i>BioMed Research International</i> , 2014, 2014, 1-17.	0.9	17
49	Osteoponin Promoter Controlled by DNA Methylation: Aberrant Methylation in Cloned Porcine Genome. <i>BioMed Research International</i> , 2014, 2014, 1-16.	0.9	10
50	Traditional Chinese medicine application in HIV: an in silico study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2014, 32, 1-12.	2.0	29
51	Discovery of novel insomnia leads from screening traditional Chinese medicine database. <i>Journal of Biomolecular Structure and Dynamics</i> , 2014, 32, 776-791.	2.0	20
52	Molecular level activation insights from a NR2A/NR2B agonist. <i>Journal of Biomolecular Structure and Dynamics</i> , 2014, 32, 683-693.	2.0	9
53	May disordered protein cause serious drug side effect?. <i>Drug Discovery Today</i> , 2014, 19, 367-372.	3.2	37
54	Chalcone Derivatives Inhibit Human Platelet Aggregation and Inhibit Growth in Human Bladder Cancer Cells. <i>Biological and Pharmaceutical Bulletin</i> , 2014, 37, 1191-1198.	0.6	17

#	ARTICLE	IF	CITATIONS
55	Developing Hypothetical Inhibition Mechanism of Novel Urea Transporter B Inhibitor. Scientific Reports, 2014, 4, 5775.	1.6	15
56	How to design a drug for the disordered proteins?. Drug Discovery Today, 2013, 18, 910-915.	3.2	71
57	Investigation of silent information regulator 1 (Sirt1) agonists from Traditional Chinese Medicine. Journal of Biomolecular Structure and Dynamics, 2013, 31, 1207-1218.	2.0	19
58	Memory enhancement by traditional Chinese medicine?. Journal of Biomolecular Structure and Dynamics, 2013, 31, 1411-1439.	2.0	6
59	Chapter 5. When Modern Computational Systems Biology Meets Traditional Chinese Medicine. RSC Drug Discovery Series, 2013, , 61-80.	0.2	0
60	Han ethnicity-specific type 2 diabetic treatment from traditional Chinese medicine?. Journal of Biomolecular Structure and Dynamics, 2013, 31, 1219-1235.	2.0	18
61	Drug Design for Neuropathic Pain Regulation from Traditional Chinese Medicine. Scientific Reports, 2013, 3, 844.	1.6	57
62	A possible strategy against head and neck cancer:in silicoinvestigation of three-in-one inhibitors. Journal of Biomolecular Structure and Dynamics, 2013, 31, 1358-1369.	2.0	7
63	A Novel Integrated Framework and Improved Methodology of Computer-Aided Drug Design. Current Topics in Medicinal Chemistry, 2013, 13, 965-988.	1.0	62
64	Mechanism of BAG1 repair on Parkinsonâ€™s disease-linked DJ1 mutation. Journal of Biomolecular Structure and Dynamics, 2012, 30, 1-12.	2.0	12
65	A Novel Algorithm for Identification of Activated Cryptic 5â€™ Splice Sites. Journal of Biomolecular Structure and Dynamics, 2012, 29, 1089-1099.	2.0	3
66	Three-in-one agonists for PPAR-Î±, PPAR-Î³, and PPAR-Î³ from traditional Chinese medicine. Journal of Biomolecular Structure and Dynamics, 2012, 30, 662-683.	2.0	43
67	Traditional Chinese medicine as dual guardians against hypertension and cancer?. Journal of Biomolecular Structure and Dynamics, 2012, 30, 299-317.	2.0	13
68	In Silico Investigation of Potential Src Kinase Ligands from Traditional Chinese Medicine. PLoS ONE, 2012, 7, e33728.	1.1	22
69	In Silico Identification of Potent Pancreatic Triacylglycerol Lipase Inhibitors from Traditional Chinese Medicine. PLoS ONE, 2012, 7, e43932.	1.1	21
70	Uroporphyrinogen Decarboxylase as a Potential Target for Specific Components of Traditional Chinese Medicine: A Virtual Screening and Molecular Dynamics Study. PLoS ONE, 2012, 7, e50087.	1.1	28
71	High performance screening, structural and molecular dynamics analysis to identify H1 inhibitors from TCM Database@Taiwan. Molecular BioSystems, 2011, 7, 3366.	2.9	38
72	Stroke prevention by traditional Chinese medicine? A genetic algorithm, support vector machine and molecular dynamics approach. Soft Matter, 2011, 7, 4001.	1.2	57

#	ARTICLE	IF	CITATIONS
73	Lose Weight with Traditional Chinese Medicine? Potential Suppression of Fat Mass and Obesity-Associated Protein. <i>Journal of Biomolecular Structure and Dynamics</i> , 2011, 29, 471-483.	2.0	17
74	Traditional Chinese medicine, a solution for reducing dual stroke risk factors at once?. <i>Molecular BioSystems</i> , 2011, 7, 2711.	2.9	39
75	In silico pharmacology suggests ginger extracts may reduce stroke risks. <i>Molecular BioSystems</i> , 2011, 7, 2702.	2.9	47
76	Screening from the world's largest TCM database for inhibiting DNA repair protein XRCC4. <i>Molecular Simulation</i> , 2011, 37, 503-509.	0.9	2
77	Drug discovery for DNA break repair system by screening from TCM database and molecular dynamics approach. <i>Molecular Simulation</i> , 2011, 37, 804-811.	0.9	4
78	iSMART: An Integrated Cloud Computing Web Server for Traditional Chinese Medicine for Online Virtual Screening, <i>de novo</i> Evolution and Drug Design. <i>Journal of Biomolecular Structure and Dynamics</i> , 2011, 29, 243-250.	2.0	59
79	Screening from the World's Largest TCM Database Against H1N1 Virus. <i>Journal of Biomolecular Structure and Dynamics</i> , 2011, 28, 773-786.	2.0	44
80	Structure-based and ligand-based drug design for microsomal prostaglandin E synthase-1 inhibitors. <i>Molecular Simulation</i> , 2011, 37, 226-236.	0.9	6
81	Screening from TCM Database@Taiwan and QSAR model for identifying HER2 inhibitors. <i>Molecular Simulation</i> , 2011, 37, 884-892.	0.9	7
82	Potent Inhibitor Design Against H1N1 Swine Influenza: Structure-based and Molecular Dynamics Analysis for M2 Inhibitors from Traditional Chinese Medicine Database. <i>Journal of Biomolecular Structure and Dynamics</i> , 2011, 28, 471-482.	2.0	53
83	Key features for designing M2 proton channel anti swine flu inhibitors. <i>Journal of the Taiwan Institute of Chemical Engineers</i> , 2011, 42, 701-708.	2.7	6
84	TCM Database@Taiwan: The World's Largest Traditional Chinese Medicine Database for Drug Screening In Silico. <i>PLoS ONE</i> , 2011, 6, e15939.	1.1	677
85	Investigation into Potent Inflammation Inhibitors from Traditional Chinese Medicine. <i>Chemical Biology and Drug Design</i> , 2011, 78, 679-688.	1.5	52
86	iScreen: world's first cloud-computing web server for virtual screening and de novo drug design based on TCM database@Taiwan. <i>Journal of Computer-Aided Molecular Design</i> , 2011, 25, 525-531.	1.3	127
87	Drug design for hemagglutinin: Screening and molecular dynamics from traditional Chinese medicine database. <i>Journal of the Taiwan Institute of Chemical Engineers</i> , 2011, 42, 563-571.	2.7	11
88	Drug design for mPGES-1 from traditional Chinese medicine database: A screening, docking, QSAR, molecular dynamics, and pharmacophore mapping study. <i>Journal of the Taiwan Institute of Chemical Engineers</i> , 2011, 42, 580-591.	2.7	9
89	Treat Alzheimer's disease by traditional Chinese medicine?. <i>Molecular Simulation</i> , 2011, 37, 923-931.	0.9	2
90	Novel hemagglutinin inhibitors for H1N1 influenza virus screening from TCM database. <i>Molecular Simulation</i> , 2011, 37, 361-368.	0.9	8

#	ARTICLE	IF	CITATIONS
91	Molecular dynamics analysis of potent inhibitors of M2 proton channel against H1N1 swine influenza virus. <i>Molecular Simulation</i> , 2011, 37, 250-256.	0.9	10
92	Two Birds with One Stone? Possible Dual-Targeting H1N1 Inhibitors from Traditional Chinese Medicine. <i>PLoS Computational Biology</i> , 2011, 7, e1002315.	1.5	76
93	Identification of Potent EGFR Inhibitors from TCM Database@Taiwan. <i>PLoS Computational Biology</i> , 2011, 7, e1002189.	1.5	85
94	Identifying HER2 Inhibitors from Natural Products Database. <i>PLoS ONE</i> , 2011, 6, e28793.	1.1	36
95	Current developments of computer-aided drug design. <i>Journal of the Taiwan Institute of Chemical Engineers</i> , 2010, 41, 623-635.	2.7	123
96	Drug design for Influenza A virus subtype H1N1. <i>Journal of the Taiwan Institute of Chemical Engineers</i> , 2010, 41, 8-15.	2.7	26
97	Bioinformatics, chemoinformatics, and pharmainformatics analysis of HER2/HSP90 dual-targeted inhibitors. <i>Journal of the Taiwan Institute of Chemical Engineers</i> , 2010, 41, 143-149.	2.7	29
98	Computational screening and QSAR analysis for design of AMP-activated protein kinase agonist. <i>Journal of the Taiwan Institute of Chemical Engineers</i> , 2010, 41, 352-359.	2.7	15
99	Chemical engineering research in Taiwan in 2007-2009. <i>Journal of the Taiwan Institute of Chemical Engineers</i> , 2010, 41, 244-245.	2.7	1
100	Insights into designing the dual-targeted HER2/HSP90 inhibitors. <i>Journal of Molecular Graphics and Modelling</i> , 2010, 29, 21-31.	1.3	63
101	Structure-Based and Ligand-Based Drug Design for HER 2 Receptor. <i>Journal of Biomolecular Structure and Dynamics</i> , 2010, 28, 23-37.	2.0	84
102	Application of bioactivity database of Chinese herbal medicine on the therapeutic prediction, drug development, and safety evaluation. <i>Journal of Ethnopharmacology</i> , 2010, 132, 429-437.	2.0	38
103	A Novel Strategy for Designing the Selective PPAR Agonist by the "Sum of Activity" Model. <i>Journal of Biomolecular Structure and Dynamics</i> , 2010, 28, 187-200.	2.0	59
104	Is that Possible to Design the Versatile Inhibitors for H1N1, H5N1, H5N2, and H5N7?. , 2009, , .		0
105	Could Traditional Chinese Medicine Used for Curing Erectile Dysfunction?. , 2009, , .		0
106	Reducing without Side Effects? A Novel Strategy for Designing the PPAR Agonists. , 2009, , .		1
107	What is the Key Point for Designing HER2 Inhibitors?. , 2009, , .		0
108	Drug Design for AMP-Activated Protein Kinase Agonists in Silico. , 2009, , .		0

#	ARTICLE	IF	CITATIONS
109	Computational screening and design of traditional Chinese medicine (TCM) to block phosphodiesterase-5. <i>Journal of Molecular Graphics and Modelling</i> , 2009, 28, 261-269.	1.3	52
110	Magnolol encapsulated by different acyl chain length of liposomes on inhibiting proliferation of smooth muscle cells. <i>Journal of the Taiwan Institute of Chemical Engineers</i> , 2009, 40, 380-386.	2.7	6
111	Discovery of potent inhibitors for phosphodiesterase 5 by virtual screening and pharmacophore analysis. <i>Acta Pharmacologica Sinica</i> , 2009, 30, 1186-1194.	2.8	43
112	De novo design of novel selective COX-2 inhibitors: From virtual screening to pharmacophore analysis. <i>Journal of the Taiwan Institute of Chemical Engineers</i> , 2009, 40, 55-69.	2.7	24
113	Pharmacoinformatics approach for mPGES-1 in anti-inflammation by 3D-QSAR pharmacophore mapping. <i>Journal of the Taiwan Institute of Chemical Engineers</i> , 2009, 40, 155-161.	2.7	33
114	Chemoinformatics and pharmacoinformatics approach for exploring the GABA-A agonist from Chinese herb suanzaoren. <i>Journal of the Taiwan Institute of Chemical Engineers</i> , 2009, 40, 36-47.	2.7	47
115	Drug Design for XRCC4 in Silico. , 2009, , .		0
116	Ligand-Based Dual Target Drug Design for H1N1: Swine Flu- A Preliminary First Study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2009, 27, 171-178.	2.0	84
117	Drug Design for KU86 in DNA Break Repair System. , 2009, , .		0
118	Drug Design for the Influenza A Virus Subtype H1N1. , 2009, , .		0
119	A Novel Strategy for Designing Dual-Target Inhibitors of KU86 and XRCC4. , 2009, , .		0
120	Dual-Targeted Drug Design of HER2 and HSP90 by CoMFA Model and Pharmacophore Analysis. , 2009, , .		0
121	Weighted Equation and Rulesâ€”A Novel Concept for Evaluating Protein-Ligand Interaction. <i>Journal of Biomolecular Structure and Dynamics</i> , 2009, 27, 271-282.	2.0	69
122	Inhibiting the vascular smooth muscle cells proliferation by EPC and DPPC liposomes encapsulated magnolol. <i>Journal of the Taiwan Institute of Chemical Engineers</i> , 2008, 39, 407-411.	1.4	18
123	A novel perspective on designing the inhibitor of HER2 receptor. <i>Journal of the Taiwan Institute of Chemical Engineers</i> , 2008, 39, 291-299.	1.4	28
124	Insights into the suanzaoren mechanismâ€”From constructing the 3D structure of GABA-A receptor to its binding interaction analysis. <i>Journal of the Taiwan Institute of Chemical Engineers</i> , 2008, 39, 663-671.	1.4	41
125	Discovery of novel inhibitors for c-Met by virtual screening and pharmacophore analysis. <i>Journal of the Taiwan Institute of Chemical Engineers</i> , 2008, 39, 617-624.	1.4	36
126	Exploring 3D-QSAR pharmacophore mapping of azaphenanthrenone derivatives for mPGES-1 inhibition Using HypoGen technique. , 2008, , .		2

#	ARTICLE	IF	CITATIONS
127	Antiplatelet Effect and Selective Binding to Cyclooxygenase by Molecular Docking Analysis of 3-Alkylaminopropoxy-9,10-anthraquinone Derivatives. <i>Biological and Pharmaceutical Bulletin</i> , 2008, 31, 1547-1551.	0.6	16
128	Antiplatelet Effect and Selective Binding to Cyclooxygenase (COX) by Molecular Docking Analysis of Flavonoids and Lignans. <i>International Journal of Molecular Sciences</i> , 2007, 8, 830-841.	1.8	29
129	Novel selective inhibitors of hydroxyxanthone derivatives for human cyclooxygenase-2. <i>Acta Pharmacologica Sinica</i> , 2007, 28, 2027-2032.	2.8	30